Dr Antonio Pardiñas

Overview

My research is based around the role of genetic factors in the development of psychiatric disorders. Within the MRC Centre, I have worked with Professor James Walters for several years on treatment-resistant schizophrenia (TRS), widely recognised as the most disabling form of this disorder. I am a member of the Psychosis Research Theme and collaborate frequently with the Schizophrenia Working Group of the Psychiatric Genomics Consortium. I am also involved in the development of the CRIS system with NCMH and Cardiff and Vale University Health Board.

Recently, I have been supported by an Academy of Medical Sciences Springboard Award to lead a project on "Pharmacogenomics of Antipsychotic Treatment and Response" (PATRON, 2020-2023), which will be focused on the antipsychotic clozapine. Clozapine is the only drug licensed in the UK for the treatment of TRS. While it is known to improve the symptoms of many individuals, is also underprescribed and treatment is often abandoned early on the basis of poor efficacy or adverse side effects. The PATRON project aims to understand why this happens, and translate any new knowledge into a more effective use of this medication.

Researchers can find data related to publications I have been involved with in the Walters Group website.